INTRODUCTION: Previous studies have suggested the use of soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. The aim of this study was to assess the sCD26 concentration in a large cohort to evaluate its association to epidemiologic parameters and CRC-related symptoms/pathologies. SUBJECTS AND METHODS: Serum samples were collected from 2,754 putatively healthy individuals with ages ranging from 30-65 years, and with personal or familial history of polyps, CRC and/or CR symptoms. sCD26 levels were measured by ELISA. RESULTS: No association was found between the sCD26 concentration and age (< 50 and 50), the personal or familial history of polyps or CRC, rectal bleeding, haemorrhoids or diverticula. However, sCD26 was related to non-inflammatory benign pathologies (excluding rectal bleeding, changes in bowel habits, haemorrhoids, diverticula) and to inflammatory benign pathologies. DISCUSSION: Our results confirm that the sCD26 can be easily offered and evaluated in a large cohort. Additionally, the validation of sCD26 as a tumour marker for screening and case-finding purposes requires a further comparison with an established non-invasive test like the faecal occult blood.
INTRODUCTION: Previous studies have suggested the use of soluble CD26 (sCD26) as a tumour marker for the detection of colorectal cancer (CRC) and advanced adenomas. The aim of this study was to assess the sCD26 concentration in a large cohort to evaluate its association to epidemiologic parameters and CRC-related symptoms/pathologies. SUBJECTS AND METHODS: Serum samples were collected from 2,754 putatively healthy individuals with ages ranging from 30-65 years, and with personal or familial history of polyps, CRC and/or CR symptoms. sCD26 levels were measured by ELISA. RESULTS: No association was found between the sCD26 concentration and age (< 50 and 50), the personal or familial history of polyps or CRC, rectal bleeding, haemorrhoids or diverticula. However, sCD26 was related to non-inflammatory benign pathologies (excluding rectal bleeding, changes in bowel habits, haemorrhoids, diverticula) and to inflammatory benign pathologies. DISCUSSION: Our results confirm that the sCD26 can be easily offered and evaluated in a large cohort. Additionally, the validation of sCD26 as a tumour marker for screening and case-finding purposes requires a further comparison with an established non-invasive test like the faecal occult blood.
Authors: Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal Journal: World J Clin Oncol Date: 2011-06-10
Authors: Loretta De Chiara; Ana M Rodríguez-Piñeiro; Francisco J Rodríguez-Berrocal; Oscar J Cordero; David Martínez-Ares; María Páez de la Cadena Journal: BMC Cancer Date: 2010-06-28 Impact factor: 4.430
Authors: Oscar J Cordero; Rubén Varela-Calviño; Tania López-González; Cristina Calviño-Sampedro; Juan E Viñuela; Coral Mouriño; Íñigo Hernández-Rodríguez; Marina Rodríguez-López; Bruno Aspe de la Iglesia; José María Pego-Reigosa; José María Pego Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240
Authors: Sonia Blanco-Prieto; Lorena Vázquez-Iglesias; Mar Rodríguez-Girondo; Leticia Barcia-Castro; Alberto Fernández-Villar; María Isabel Botana-Rial; Francisco Javier Rodríguez-Berrocal; María Páez de la Cadena Journal: PLoS One Date: 2015-05-18 Impact factor: 3.240
Authors: Loretta De Chiara; María Páez de la Cadena; Javier Rodríguez-Berrocal; Mª Carmen Alvarez-Pardiñas; Mª Carmen Pardiñas-Añón; Rubén Varela-Calviño; Oscar J Cordero Journal: Dis Markers Date: 2020-01-21 Impact factor: 3.434
Authors: Loretta De Chiara; Ana M Rodríguez-Piñeiro; Oscar J Cordero; Lidia Vázquez-Tuñas; Daniel Ayude; Francisco J Rodríguez-Berrocal; María Páez de la Cadena Journal: PLoS One Date: 2014-09-11 Impact factor: 3.240